SOX2 and carcinoma: Compared to Sox2-negative FMCs, Sox2-positive carcinomas were associated with an almost 2-fold increased risk of distant metastasis over time (HR = 1.87, 95% CI 1.00–3.51, p = 0.0398, Figure 2A).